Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Patrick W. Mellors, Moritz Binder, Francis K. Buadi, Martha Lacy, Morie Gertz, Angela Dispenzieri, Suzanne R. Hayman, Prashant Kapoor, Wilson Gonsalves, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Taxiarchis Kourelis, Rahma Warsame, Steven R. Zeldenrust, John A. Lust, Nelson Leung, Ronald S. Go, Robert A. Kyle, S Vincent RajkumarShaji K Kumar

Research output: Contribution to journalArticle

Abstract

The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019

Keywords

  • Multiple myeloma
  • prognosis
  • response
  • survival
  • thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

  • Cite this